TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: favorable modified Rankin Score (less than or equal to 2)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Solicited Injection Site Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Unsolicited Injection Site Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with mRS ≤1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily morphine equivalent dose consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Algorithm accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shock Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Unanticipated adverse device effects (UADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Peak change in serum creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum tolerated dose of vemurafenib
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in Mean Cold Air VAS Stimulus Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a loss of response to hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of safety based on treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of time of plasma glucose levels spent in target range (2.5 mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of time of plasma glucose levels spent in target range (5 mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to Study Medication at 24-hr NPRS Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ReQuest(tm) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concentration of anti-SARS-CoV-2 spike protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Infection rate of COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in visceral fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Patients With a Given Tumour Genetic and Proteomic Marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Patients Who Experienced at Least One System-generated Error Based on the Controller Data While Using the Zalviso System
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Who Rate the Patient Global Assessment (PGA) of Method of Pain Control Over 24 Hours as Good or Excellent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time-weighted Summed Pain Intensity Difference (SPID) Over the 24-hour Study Period (SPID24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration until development of CRPC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline King's Health QoL questionnaire score after treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline Post-void residual urine after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline Maximum Cystometric Capacity (MCC) after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline Maximum Flow Rate (Qmax) after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline Detrusor pressure at maximum flow rate (Pdet @Qmax) after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sum of Pain Intensity Difference (SPIDnorm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of stress urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Interface side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of satisfaction of the patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-PCI changes in markers of endothelial damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-PCI changes in markers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in multi-focal ERG response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients reaching remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported levels of perceived stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reported levels of resiliency
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reported levels of participants Sense of Support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Sustained Virologic Response at 12 Weeks Post Treatment Discontinuation (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Completed 4 Weeks of Treatment Without Discontinuation Due to AEs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gut acute Graft-versus-Host Disease (aGvHD) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Eckardt Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of respiratory morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of belated non-infectious pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients with HIV RNA less than 400 copies per ml and less than 50 copies per ml at month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmin and Cmax for the three drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or 4 undesirable effects frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Knee trouble/pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in insomnia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in daytime impairment secondary to insomnia
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in fatigue, depression and mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in NKT marker Valpha24 mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adoption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrences of grade 3 or higher toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percent correct for target speech sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Strength (peak force)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of perioperative hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Daily Pain Severity Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance travelled during the 2MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS) for walking ankle pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of diagnoses performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in AHI (apnea-hypopnea index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cmax of FCN-411 following single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of FCN-411 following single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of FCN-411 following single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Working speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Workload perception
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Urinary excretion of amikacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Score on the Forward-Step-Down Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability measured using QuickDASH
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Need for peroral analgesia after the chest tube removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of correct answers in the oral version of the Symbol Digit Modalities Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in Gastrointestinal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mucosal Injury Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: extent of endothelial damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in Average Daily Frequency of Moderate to Severe Vasomotor Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in The Number of T Regulatory Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Whole body muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of DDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 3 or Grade 4 Adverse Events and Laboratory Abnormalities Defined as Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate - Investigator Assessment
Endpoint domain: Physiological/clinical
Primary endpoint: Number of flashbacks recorded
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean sexual function domain score
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Patient reported satisfaction with clinical encounter
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: neuronal coherence in basal ganglia structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maintenance of Wakefulness Test (MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients That Were Very Much Improved or Much Improved on Clinical Global Impression of Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Cataplexy Attacks at Visit 8 (Week 14) as Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Resting Energy Expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Two (2) year incidence of stroke or Hard TIA
Endpoint domain: Mortality/survival
Primary endpoint: All cause mortality for the first 30 days of follow up/discharge, whichever is longer
Endpoint domain: Mortality/survival
Primary endpoint: Neurological mortality from 31 days of follow up (F/U) or longer
Endpoint domain: Mortality/survival
Primary endpoint: Inflammatory Lesion Count (Papules and Pustules)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Corneometer Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Tewameter Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: SKAMP deportment rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with treatment-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in bone width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Effectiveness of study-based care vs usual care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Self-efficacy change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Potentially Clinically Significant Abnormalities in Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Potentially Clinically Significant Abnormalities in Electrocardiogram (ECG) Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 max variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: T-cell responses against beta-cell antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Score of the Fibromyalgia Impact Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Objective Response Rate (ORR:CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recovery of smell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants readmitted within 30 days of surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Arterial blood gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who DID NOT Experience Disease Progression or Death
Endpoint domain: Mortality/survival
Primary endpoint: Three-year Relapse-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Five-year Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean maximal NRS score for pain during ECV procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal redetachment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Blood flow perfusion changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline OSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visceral fat gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: upper body subcutaneous fat gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of OPA-15406 in a Single Administration Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of OPA-15406 in the Multiple Administration Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contentment with the intervention - Patient
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of Life: KIDSCREEN-27 Barne/ungdomsversjon 8-18år
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Duration of Complete Cytogenetic Response (CCgR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients With Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated laser fluence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Physical Examination Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Change From Baseline in 12-lead Electrocardiograms (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Vital Sign Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Abnormalities in Laboratory Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent body mass loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of genes involved in vasospasm of primary Raynaud's phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cross sectional area of the Rectus Femoris (RFcsa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hand Held Dynamometry strength (grip strength)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference in thigh girth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep bruxism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Obstructive sleep apnea syndrome (SAOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients achieving sustainable post thrombolytic blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Stroke Impact Scale (SIS) Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Device Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Global Executive Composite T-Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of late severe gastrointestinal toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of late severe genitourinary toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensitivity and specificity of host-related individual biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of subsequent bloodstream infections (BSI) or invasive infections
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of recruitment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of obtaining SNP data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of integrating SNP data into EMR
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patients' VR experience and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Application preference regarding VR types
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Motor Function of the Affected Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of Hu5F9-G4
Endpoint domain: Adverse events/effects
Primary endpoint: Gene expression measurements in skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density and distribution of Imidazoline 2 binding sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI Quadriceps Involved Leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MRI Quadriceps Contralateral Leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MRI Hamstrings Involved Leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MRI Hamstrings Contralateral Leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Roland Morris Disability Questionnaire (RMDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Percent Reduction in Cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 20 Response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit and Reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Straight Leg Raise Passive Knee Extension Test (PKE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Oswestry Disability Index (ODI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tinnitus handicap inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status